Free Trial
TSE:EPI

ESSA Pharma (EPI) Stock Price, News & Analysis

→ Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad)
Free EPI Stock Alerts
C$0.32
-0.01 (-3.03%)
(As of 12/1/2017)
Today's Range
C$0.32
▼
C$0.34
50-Day Range
C$0.32
▼
C$0.32
52-Week Range
C$0.31
▼
C$4.60
Volume
4,700 shs
Average Volume
68,239 shs
Market Capitalization
C$9.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About ESSA Pharma

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.

EPI Stock Price History

EPI Stock News Headlines

April 27, 2024 | msn.com
Does Insurance Cover EpiPens?
April 7, 2024 | uk.investing.com
ESSA Pharma Inc (EPIX)
April 29, 2024 | Prosper Trading Academy (Ad)
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
January 30, 2024 | realmoney.thestreet.com
Essa Pharma initiated with bullish view at JonesResearch, here's why
January 26, 2024 | finance.yahoo.com
EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…
January 26, 2024 | msn.com
What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?
January 25, 2024 | finanznachrichten.de
ESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
January 25, 2024 | finance.yahoo.com
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
April 29, 2024 | Prosper Trading Academy (Ad)
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
December 12, 2023 | finance.yahoo.com
ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...
November 23, 2023 | finance.yahoo.com
Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares
November 7, 2023 | seekingalpha.com
ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance
October 24, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)
October 6, 2023 | benzinga.com
Prostate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
September 20, 2023 | seekingalpha.com
ESSA Pharma files for $200M mixed shelf offering - filing
August 9, 2023 | msn.com
Oppenheimer Reiterates Essa Pharma (EPIX) Outperform Recommendation
April 4, 2023 | msn.com
Why are EpiPens still so expensive?
February 13, 2023 | finance.yahoo.com
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
December 19, 2022 | finance.yahoo.com
EPIX: Advancing Multiple Clinical Trials in 2023…
November 16, 2022 | seekingalpha.com
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer
October 31, 2022 | marketwatch.com
Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials
October 31, 2022 | seekingalpha.com
ESSA drops 26% as Johnson & Johnson ends trial enrollment for lead asset
October 26, 2022 | finance.yahoo.com
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | marketwatch.com
ESSA Pharma Surges 152% on Study Results for Lead Drug Candidate
October 26, 2022 | finance.yahoo.com
Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | seekingalpha.com
ESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapy
August 10, 2022 | finance.yahoo.com
EPIX: Multiple Ongoing Studies of EPI-7386…
See More Headlines
Receive EPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
TSE:EPI
CUSIP
N/A
CIK
N/A
Web
essapharmaceuticals.com
Phone
+1-778-3310962
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
29,102,000
Free Float
N/A
Market Cap
C$9.31 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Richard M. Glickman LL.D. (Age 57)
    Chairman of the Board
  • David Ross Parkinson M.D. (Age 67)
    President, Chief Executive Officer, Director
  • David Wood (Age 57)
    Chief Financial Officer
  • Peter Virsik
    Chief Operating Officer, Executive Vice President
  • Raymond L. Andersen (Age 67)
    Chief Technology Officer, Director
  • Marianne D. Sadar (Age 53)
    Chief Scientific Officer, Director
  • Frank Perabo (Age 50)
    Chief Medical Officer
  • Franklin M. Berger (Age 67)
    Director
  • Scott Requadt J.D.
    Director
  • Gary Sollis (Age 61)
    Director

Insiders


EPI Stock Analysis - Frequently Asked Questions

How have EPI shares performed in 2024?

ESSA Pharma's stock was trading at C$0.32 at the beginning of 2024. Since then, EPI stock has increased by 0.0% and is now trading at C$0.32.
View the best growth stocks for 2024 here.

Is ESSA Pharma a good dividend stock?

ESSA Pharma (TSE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), bluebird bio (BLUE), Gray Television (GTN), Allergan (AGN), Cardiome Pharma (CRME), CEMEX (CX), Groupon (GRPN), Horizon Therapeutics Public (HZNP) and Tandem Diabetes Care (TNDM).

How do I buy shares of ESSA Pharma?

Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EPI) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
His win rate puts Warren Buffett to shame…
Investing Daily
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
This AI Trade Machine Made 1,729%* (With 89% Wins)
Prosper Trading Academy
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Has Jeff Bezos Found the Next Nvidia?
InvestorPlace